RAC 2.20% $1.78 race oncology ltd

Cardioprotection thread, page-81

  1. 19,268 Posts.
    lightbulb Created with Sketch. 6358
    Yes I have considered this in the past. This combo is incredibly effective at treating the cancer, but it comes with a very high cardiac risk. Bisantrene might be able to change this by keeping the anticancer efficacy, but minimising the cardiac damage.

    The complication is the introduction of Enhertu which has upturned the whole HER2 treatment landscape.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.